MARKET

OMGA

OMGA

Omega Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.390
+0.770
+21.27%
After Hours: 4.300 -0.09 -2.05% 18:44 06/24 EDT
OPEN
3.630
PREV CLOSE
3.620
HIGH
4.390
LOW
3.255
VOLUME
2.54M
TURNOVER
0
52 WEEK HIGH
31.41
52 WEEK LOW
1.975
MARKET CAP
210.05M
P/E (TTM)
-2.4921
1D
5D
1M
3M
1Y
5Y
Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer
Omega Therapeutics, Inc.
Benzinga · 2d ago
Encompass Health (EHC) Plans to Distribute Enhabit Shares
Every Encompass Health (EHC) shareholder will receive one Enhabit common share for every two EHC common shares held.
Zacks · 06/15 18:58
Omega Therapeutics Submits IND For Liver Cancer Candidate
Omega Therapeutics, Inc. (NASDAQ: OMGA) submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its lead product candidate, OTX-2002, for the treatment of hepatocellular carcinoma (HCC).
Benzinga · 06/15 12:20
Omega seeks FDA nod to start liver cancer trial of lead drug OTX-2002
Omega Therapeutics (NASDAQ:OMGA) submitted an investigational new drug application to the U.S. Food and Drug Administration (FDA) to get clearance to start a clinical trial of its lead product candidate
Seekingalpha · 06/15 11:18
BRIEF-Omega Therapeutics Submits IND Application For OTX-2002 For MYC Driven Hepatocellular Carcinoma
reuters.com · 06/15 11:15
Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma
Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega") today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Company's lead product candidate, OTX-2002, for the treatment of hepato...
PR Newswire · 06/15 11:00
Omega Therapeutics Submits Investigational New Drug Application to US FDA for OTX-2002 for Hepatocellular Carcinoma
MT Newswires · 06/15 07:36
91 Biggest Movers From Friday
Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.
Benzinga · 06/13 08:28
More
No Data
Learn about the latest financial forecast of OMGA. Analyze the recent business situations of Omega Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
25.00%Buy
25.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average OMGA stock price target is 16.25 with a high estimate of 30.00 and a low estimate of 4.000.
High30.00
Average16.25
Low4.000
Current 4.390
EPS
Actual
Estimate
-2.69-2.02-1.34-0.67
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 50
Institutional Holdings: 43.54M
% Owned: 91.00%
Shares Outstanding: 47.85M
TypeInstitutionsShares
Increased
20
2.11M
New
10
114.14K
Decreased
9
415.32K
Sold Out
5
740.72K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Chairman/Co-Founder/Director
Noubar Afeyan
President/Chief Executive Officer/Director
Mahesh Karande
Chief Financial Officer
Joshua Reed
Chief Human Resource Officer
Kevin McManus
Chief Administrative Officer/Secretary
Ling Zeng
Chief Scientific Officer
Thomas McCauley
Other
Yan Moore
Independent Director
Luke Beshar
Independent Director
Elliott Levy
Independent Director
John Mendlein
Independent Director
Mary Szela
Independent Director
Richard Young
No Data
No Data
About OMGA
Omega Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused in a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to fundamentally transform human medicine in the service of patients. It is developing OMEGA Epigenomic Programming platform is designed to coopt nature's universal operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The Company have deciphered the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and evolutionarily conserved structures called Insulated Genomic Domains (IGDs). The OMEGA platform enables to systematically identify and validate thousands of DNA-sequence-based epigenomic zip codes within IGDs. The Company's pipeline consists of early-stage, preclinical programs that span regenerative medicine, multigenic diseases including immunology, oncology, and select monogenic diseases.

Webull offers kinds of Omega Therapeutics Inc stock information, including NASDAQ:OMGA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OMGA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OMGA stock methods without spending real money on the virtual paper trading platform.